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Abstract
MELODI (Multidisciplinary European Low Dose Initiative) is a European radiation protection research platform with focus 
on research on health risks after exposure to low-dose ionising radiation. It was founded in 2010 and currently includes 44 
members from 18 countries. A major activity of MELODI is the continuous development of a long-term European Strategic 
Research Agenda (SRA) on low-dose risk for radiation protection. The SRA is intended to identify priorities for national 
and European radiation protection research programs as a basis for the preparation of competitive calls at the European level. 
Among those key priorities is the improvement of health risk estimates for exposures close to the dose limits for workers 
and to reference levels for the population in emergency situations. Another activity of MELODI is to ensure the availability 
of European key infrastructures for research activities, and the long-term maintenance of competences in radiation research 
via an integrated European approach for training and education. The MELODI SRA identifies three key research topics in 
low dose or low dose-rate radiation risk research: (1) dose and dose rate dependence of cancer risk, (2) radiation-induced 
non-cancer effects and (3) individual radiation sensitivity. The research required to improve the evidence base for each of 
the three key topics relates to three research lines: (1) research to improve understanding of the mechanisms contributing to 
radiogenic diseases, (2) epidemiological research to improve health risk evaluation of radiation exposure and (3) research to 
address the effects and risks associated with internal exposures, differing radiation qualities and inhomogeneous exposures. 
The full SRA and associated documents can be downloaded from the MELODI website (http://www.melodi-online.eu/sra.
html).
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Introduction
Exposure to ionising radiation from natural and/or arti-
ficial sources is ubiquitous and unavoidable. Medical 
and natural sources represent the largest fractions of the 
average effective dose received by the general public 
(UNSCEAR 2008). Exposures to artificial sources can 
vary between individuals depending on their occupation 
(e.g. employment in the nuclear industry, in air transport 
and in medicine), their health status (leading to varying 
medical exposures) and in rare cases on their place of 
living (due to potential environmental contamination). 
In addition to the fact that ionising radiation is unavoid-
able and variable in the population, it is known to dam-
age health at certain exposure levels. At very high doses 
(> 1 Gy whole body) ionising radiation can be acutely 
lethal, while it can induce tissue damage following more 
localized high-dose exposures (ICRP 2012, AGIR 2009). 
Fortunately, those exposures are very rare. However, tissue 
damage can occur in various organs following life-saving 
cancer radiotherapy, with prevalences of up to 15% of the 
patients depending on the treatment (Dörr and Hendry 
2001; Paulino et al. 2010).
Since many decades it is known that radiation can 
cause cancer in humans following acute exposure in the 
dose range of a few Sv down to about 100 mSv. More 
recently, evidence has accumulated that these more mod-
erate exposures may also contribute to other conditions 
such as circulatory disease, lens opacities and effects on 
future generations (hereditary effects) (UNSCEAR 2010). 
The cancer risks to humans are established down to about 
100 mSv, while for circulatory diseases and lens opaci-
ties they are established down to about 500 mSv (AGIR 
2010). Below these levels, especially following protracted 
or other non-homogenous exposures, the risks to human 
health are less certain. The current system of radiation 
protection developed by the International Commission 
on Radiological Protection (ICRP) aims to avoid tissue 
injury and minimize the probability for cancer and heredi-
tary disease (ICRP 2007). Risks of cancer and hereditary 
effects below 100 mSv are regulated assuming a linear 
non-threshold (LNT) relationship between dose and effect; 
however, for those low-dose exposures there is a large 
uncertainty about the exact dose response, and the impact 
of protracting exposures over long periods such as employ-
ment from, around 18 years of age to retirement.
There are various sources of ionising radiation in mod-
ern society. Medical uses of radiation for diagnostics and 
therapy are becoming increasingly prevalent. Nuclear 
power generation is viewed by many as a low-carbon diox-
ide emitting efficient energy source, and industrial radi-
ography plays important roles in safety assessment. High 
radon exposures in buildings are a major issue in many 
countries. Long-distance air travel can lead to increased 
exposures of aircrew and passengers. Other sources are 
exposures to naturally occurring radioactive materials 
(NORM) in the oil extraction and other industries.
Therefore, an appropriate and acceptable balance between 
the benefits of use of ionising radiation on the one hand 
and the potentially associated health risk on the other hand 
is indispensable. The protection of individuals and popula-
tions comes at a cost, and there are disadvantages of both 
under- and overprotection. This applies in all exposure situ-
ations—existing elevated exposure situations such as high 
radon concentrations in buildings, occupational exposure 
situations for example in nuclear industry and the medical 
sector, and accidental situations where difficult decisions 
on countermeasure implementation such as health monitor-
ing, sheltering and evacuation are required. In all of these 
contexts, it is of utmost importance that robust and accurate 
information is available on the magnitude of health risks 
posed by any given radiation doses, ranging from high to 
low. The main uncertainties in radiation health risk evalu-
ation are in the magnitude of cancer risk at low acute and 
protracted doses below 100 mSv, the magnitude of non-
cancer effects below 500 mSv and the variation in disease 
risk between individuals in the population. These are the key 
areas identified by Multidisciplinary European Low Dose 
Initiative (MELODI) requiring further research to provide 
better and more solid evidence for appropriate decision mak-
ing in all areas of radiation protection. Accurate and reliable 
health risk estimation of low dose and dose-rate exposures of 
humans is an essential foundation for a robust and acceptable 
system of radiation protection.
The European research platform MELODI
The purpose of the MELODI association is to establish 
a European research platform with a focus on health risk 
assessment after exposures to low-dose ionising radiation 
and its application for radiation protection, aiming for a 
progressive integration of national and European activities 
(http://www.melodi-online.eu/) (Repussard 2015). MELODI 
was founded in 2010 as a registered association with 15 insti-
tutional members. As of July 2017, MELODI has 44 mem-
bers from national bodies responsible for defining, funding 
and implementing radiation research, and universities and 
research institutes committed to contributing to research and 
development in this domain. MELODI contributes to the 
setting of priority objectives in low-dose risk research, to 
the establishment of research programs and identification 
of resources to be implemented in order to achieve these 
objectives. Furthermore, MELODI supports the assessment 
of results obtained, education and promotion of communi-
cation on these issues between the various parties involved 
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as well as sustainability of key research activities (Salomaa 
et al. 2015, 2017; Belli et al. 2011, 2015). Major actions of 
MELODI include organization of scientific and stakeholder 
workshops, promotion of the visibility of the research area, 
nomination of working groups on specific topics and facili-
tating collaborative research.
The establishment and regular updating of a long-term 
(> 20 years) Strategic Research Agenda (SRA) for research 
on low-dose health risk radiation protection in Europe is a 
key activity of MELODI. This SRA is supposed to provide 
guidance on the priorities for national and European research 
programmes and on the preparation of competitive calls at 
the European level. Furthermore, MELODI supports the 
availability of key infrastructures in Europe as an essential 
basis for research activities, and the long-term maintenance 
of competences in radiation research and health risk assess-
ment by means of an integrated European approach for train-
ing and education. Consequently, MELODI established three 
working groups (WGs): one on the MELODI SRA, one on 
education and training, and a third on infrastructures.
The European Network of Excellence DoReMi 
(2010–2016) funded by Euratom FP7 Radiation Protection 
Programme served as an important initial operational tool 
for establishing MELODI (Salomaa et al. 2015). Currently, 
major parts of European radiation protection research are 
being organized within the CONCERT European Joint Pro-
gramme Co-fund Action (EJP). CONCERT brings together 
funding agencies from the European Commission (EC) 
and the member states in an effort to integrate European 
radiation protection research and launches research calls 
in radiation protection on behalf of the EC. An important 
operational tool for the establishment of CONCERT was 
the European project OPERRA (Open Project for European 
Radiation Research Area, 2013–2017). Integration will 
build upon the SRAs from five European radiation protec-
tion research platforms, MELODI, ALLIANCE (radioecol-
ogy) (Hinton et al. 2013), NERIS (emergency management) 
(Schneider et al. 2016), EURADOS (dosimetry of ionising 
radiation) (Rühm et al. 2016) and EURAMED (medical 
exposures) (EURAMED 2017), and aims to establish inter-
action and synergies between these different areas of exper-
tise (Salomaa et al. 2017).
MELODI SRA
The MELODI SRA has been updated yearly since 2010, 
taking into account results of ongoing, completed and pub-
lished research, and new key radiation protection research 
issues, which may have arisen since the previous update. 
The procedure of SRA development includes that an updated 
draft and a short MELODI statement (only in years where 
a call will be launched), presenting the top priorities, is 
posted on the public MELODI website 6–8 weeks before 
the annual MELODI workshop takes place. Those interested 
(scientists, stakeholders) can then join an open consultation 
process on the MELODI website and/or participate in the 
following MELODI workshop to provide input before the 
SRA’s and statement’s revision. The first draft of a MELODI 
SRA was published in October 2010. Currently the eighth 
draft of the MELODI SRA is available on the MELODI 
website. All published MELODI SRAs can be downloaded 
from http://www.melodi-online.eu/sra.html. Summaries of 
the MELODI workshops are published (Salomaa et al. 2013; 
Aerts et al. 2014; Bouffler 2017) or can be found through the 
MELODI website.
The MELODI SRA has been developed following the key 
policy goals, to address the robustness of the current radia-
tion protection system, as defined by the High Level Expert 
Group on European Low Dose Risk Research (HLEG) 
(http://www.hleg.de/). These goals include research on: (a) 
the shape of the dose–response for cancer, (b) tissue sen-
sitivities for cancer induction, (c) individual variability in 
cancer risk, (d) the effects of radiation quality type, (e) risks 
from internal radiation exposure, and, (f) risks of, and dose 
response relationships for, non-cancer diseases and heredi-
tary effects.
For the purpose of the MELODI SRA, these issues were 
restructured into three key topics low-dose and dose-rate 
radiation health risk research:
1. Dose and dose-rate relationship for cancer;
2. non-cancer effects; and
3. individual radiation sensitivity.
As discussed by the HLEG and confirmed by the DoReMi 
Network of Excellence and MELODI, research at low dose-
rates or low doses includes major challenges in the investiga-
tion of both radiation-related health effects and underlying 
biological mechanisms, because the magnitude of health risk 
and biological effects is expected to be low. A multidisci-
plinary approach is therefore essential. For this reason, each 
key topic is sub-divided into three research lines:
• Research to improve understanding of the mechanisms 
contributing to radiation risk following low dose/dose-
rate exposures.
• Epidemiological research that integrates, where possible 
and informative, biological approaches to improve health 
risk evaluation of radiation exposure.
• Research specifically aimed to address the effects of and 
risks associated with internal exposures, different radia-
tion qualities and inhomogeneous exposures.
In the following text, the three key research topics are 
described and the research needed for an improvement of 
the evidence base for each of these topics is described based 
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on the above-mentioned three research lines. In Tables 1, 2 
and 3 the priority research areas within each key topic and 
research line are given.
Key research topic 1: “dose 
and dose‑rate‑dependence of cancer risk”
Current risk estimates used in radiation protection are 
based upon epidemiological studies of exposed populations 
(UNSCEAR 2008; Boice 2017). Radiation protection stand-
ards aim to avoid tissue reactions and minimize the inci-
dence of the late developing stochastic effects of cancers and 
hereditary effects in future generations (ICRP 2007). Thus, 
for radiological protection it is of fundamental importance 
that the health risk estimates are robust and credible. Most 
important among the epidemiological studies are the follow-
up studies on Japanese A-bomb survivors of Hiroshima and 
Nagasaki that provided clear evidence of increased cancer 
risk (Ozasa et al. 2012; Grant et al. 2017). While these 
studies remain the main basis for the cancer risk estimates 
used in radiation protection, they relate to a specific popu-
lation and a specific exposure scenario. The exposure was 
essentially an acute, high dose-rate total-body gamma ray 
exposure with a small neutron component. Therefore, the 
A-bomb survivor studies are to an increasing extent comple-
mented by occupational, environmental, and medical expo-
sure studies (UNSCEAR 2008; Shore et al. 2017), which 
allow direct investigation of effects of fractionated or more 
protracted exposures and effects of lower doses (Rühm et al. 
2015). Evidence for radiation-related hereditary effects is 
based on experimental animal studies because there is no 
direct evidence from human studies to date. The contribution 
of hereditary risk to the overall risk is estimated to be small 
in comparison with cancer risk (ICRP 2007).
Epidemiological studies provide evidence of dose-related 
increases in total cancer risk after acute exposures with 
doses of about 100 mSv and above. Recent pooled occupa-
tional studies suggest increased solid cancer and leukaemia 
risks following protracted radiation exposures of the order 
of around 100 mSv (Richardson et al. 2015; Leuraud et al. 
2015). Further, recent reports indicate a possible associa-
tion between natural background gamma radiation exposures 
and risk of childhood leukaemia (Spycher et al. 2015) and 
suggest an elevated risk associated with medical imaging 
methods (Walsh et al. 2014).
Nevertheless, there are major uncertainties concerning (1) 
the magnitude of cancer risk following protracted exposures 
encountered in the environment, in medicine and in occupa-
tional settings, particularly those of the order of 100 mSv or 
less; (2) organ-specific risks following acute or protracted 
doses of a few 100 mSv, particularly for inhomogeneous 
dose distributions; (3) the risk for specific cancer sites due Ta
bl
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to possibly different tissue sensitivities, and (4) the most 
scientifically evidence-based model to infer risks at doses 
and dose-rates lower than those for which direct epidemio-
logical evidence is available. In this context, there are also a 
number of ethical questions that need to be addressed, such 
as “precautionary” use of the LNT model for extrapolation 
to doses far below those where risk estimates are considered 
well founded on empirical observations.
Classical epidemiological studies will need to be contin-
ued to refine the direct knowledge of risk in human popula-
tions, particularly in the context of low-dose and protracted 
exposures, and internal contamination. Biologically-based 
mechanistic and epidemiological approaches should be 
combined to quantify cancer risks from acute whole body 
exposures with low dose (< 100 mSv) or from protracted or 
inhomogeneous exposures at low to moderate doses (a few 
100 mSv or less). They also need to address the impact of 
different radiation qualities and effects of both internal and 
external exposures, alone and in combination. Knowledge 
of health risks from such low dose-rate exposures is of key 
relevance for planning measures in emergency situations, 
particularly for large populations and for radiation protection 
of occupationally exposed persons, to evaluate the present 
dose limit of 20 mSv/year averaged over 5 years with no 
single year exceeding 50 mSv (EURATOM 2014).
Research line 1: basic mechanisms
An LNT extrapolation model is currently used in radiation 
protection to estimate risk at low doses from epidemiologi-
cal data obtained at higher doses (ICRP 2007; Boice 2017). 
An important aspect for the justification of using this model 
is that radiation carcinogenesis is assumed to be primar-
ily driven by damage to DNA and subsequent mutations of 
growth-regulating genes in target cells (Brenner et al. 2003). 
Yet, a number of other potential mechanisms contributing to 
and modulating radiation carcinogenesis have been proposed 
(UNSCEAR 2012) and it is important to determine their 
potential roles (Kadhim et al. 2013). The extent to which 
these modulations and non-mutational mechanisms sup-
port or challenge the validity of a LNT risk extrapolation 
model needs to be determined under relevant exposure con-
ditions. For this purpose, the use of well-validated animal 
and human cellular/tissue models of radiation carcinogenesis 
(both solid cancers and leukaemias) is required.
Research line 2: health risk evaluation
Quantification of cancer risk at moderate dose or dose-rates 
from inhomogeneous or protracted exposure, and at low 
doses or dose-rates from acute, homogenous exposure is 
a key challenge. The large size of epidemiological studies 
required to detect small increases in cancer risk at low doses 
and dose-rates and the potential for bias and confounding 
present challenges, particularly at the lowest doses (Brenner 
et al. 2003). The priorities in this area include the mainte-
nance and improvement of key cohorts by continued follow-
up, pooling of different studies, collection of information 
on confounders and reducing misclassification of dose and 
health data. Key cohorts are characterized by large popula-
tions with exposure conditions and dose distributions that 
are relevant for radiation protection, good individual dosim-
etry, long and complete follow-up with good quality data of 
health outcome, particularly on cancer occurrence; and the 
possibility of collecting information on relevant potential 
confounders either on the whole cohort or through nested 
case–control studies.
These studies should include, where possible and likely 
to be informative, the collection and appropriate storage of a 
large number of relevant biological samples, including tissue 
samples from most of the cancer cases. Through identifi-
cation and integration of relevant biological endpoints and 
markers into epidemiological studies (Pernot et al. 2012; 
Hall et al. 2017), further insights will be gained into the 
risks associated with such exposures. The integration of both 
epidemiological and mechanistic studies will improve cancer 
risk evaluation through molecular epidemiological studies 
or by mechanistic modelling.
Research line 3: impact of radiation exposure 
characteristics
It is important but often overlooked that radiation exposure 
in the environment, in occupational and medical settings can 
involve internal contamination, often to radiations of differ-
ing quality, or involve other aspects of dose inhomogene-
ity. The current system of protection uses radiation weight-
ing factors to reflect spatial dose distribution differences 
between radiations of differing quality. The actual risks 
associated with all forms of dose inhomogeneity including 
those due to inhomogeneous activity distribution within a 
tissue like in case of radon exposure (Madas 2016) are not 
well understood. The extent to which these factors modify 
dose–response relationships for cancers is therefore impor-
tant to understand.
Key research topic 2: “non‑cancer effects”
It has been traditionally assumed that health effects other 
than cancer and hereditary diseases show a threshold 
at doses that are above the levels of exposures typically 
encountered in the public environment, at work or from 
diagnostic medical uses of ionising radiation (ICRP 2012). 
Recent results from epidemiological and experimental stud-
ies indicate increased risks from vascular diseases (Little 
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2016; AGIR 2010), lens opacities (Shore 2016), cognitive/
neurological effects (Verreet et al. 2016; Hall et al. 2004); 
and others not only at doses above 5 Gy but also at a range 
of doses from 5 down to 0.5 Gy and, possibly even at lower 
doses (< 0.5 Gy) (Shore 2014). Based on these findings 
the International Commission on Radiological Protection 
(ICRP) issued in 2011 a statement on tissue reactions (for-
merly termed non-stochastic or deterministic effects) that 
noted evidence that the threshold in absorbed dose for effects 
on the lens of the eyes is in the order of 0.5 Gy (acute and 
protracted exposure). Consequently, a recommendation was 
made for a reduction in the annual equivalent dose limit for 
the lens of the eye to 20 mSv per year averaged over 5 years 
with no 1 year exceeding 50 mSv (ICRP 2012). In addition, 
ICRP suggested that the absorbed dose threshold for circu-
latory diseases may be as low as 0.5 Gy. ICRP defines the 
threshold as the dose that causes the disease in 1% of the 
exposed persons.
For all outcomes, uncertainties and concerns exist about 
possible effects at low doses, which could have important 
implications for radiation protection. Results of epidemio-
logical studies are not always consistent, as bias and con-
founding cannot be excluded, and the biological mecha-
nisms of relevance for health risks at these low doses are not 
known. The possibility of a stochastic nature of non-cancer 
effects without dose thresholds raises a wide range of ques-
tions, and needs further investigation. In contrast to cancer 
and hereditary effects, knowledge on the underlying biologi-
cal mechanisms for radiation-related non-cancer effects in 
the moderate and low-dose range is very sparse. Therefore, 
research to understand the mechanisms is necessary. In addi-
tion, careful epidemiological research based on key cohorts, 
integrating—where possible and informative—biological 
approaches is needed to provide information on radiation-
related risk of non-cancer diseases following low-dose, 
protracted or fractionated exposure, relevant for radiation 
protection. Individual radiation sensitivity, mixed exposures 
and the impact of characteristics of radiation exposure also 
need to be considered.
Research line 1: basic mechanisms
Deterministic effects or tissue reactions are classically 
thought to arise as a consequence of cell killing or func-
tional inactivation by the (generally) high radiation doses 
involved (ICRP 2012). They are characterised by steeply 
increasing dose–response relationships at doses beyond a 
defined threshold. It is unlikely that cell killing/inactiva-
tion will be the only basis for effects of lower radiation 
doses in relation to vascular disease, cataract and cogni-
tive dysfunction. Epidemiological investigations of popu-
lations with well-characterised exposures require studies 
to identify the underlying mechanisms that lead to each 
of the non-cancer disease. Each disease may have a dif-
ferent mechanistic basis, and it is not clear if there will be 
any similarity with the mechanisms that lead to radiation-
related cancers.
Research line 2: health risk evaluation
Quantification of non-cancer risk (circulatory diseases, 
lens opacities, others) in humans at moderate or low doses 
or dose-rates is a key, yet difficult challenge for radiation 
protection, because the magnitude of risk due to radia-
tion is expected to be low and the potential for bias and 
confounding is high. Informative epidemiological studies 
in this field should be characterized by large cohorts with 
exposure scenarios and dose values of interest for radia-
tion protection, good dosimetry, high quality of health 
data, long-term follow-up and the possibility of collect-
ing information on relevant potential confounders either on 
the whole cohort or through targeted nested case–control 
studies. In addition, these studies should include—where 
possible and informative—collection of a large number 
of biological samples, relevant tissue samples from most 
cases in a given organ, and extensive data on the health 
status during follow-up.
Through improvement of key epidemiological studies 
(e.g., increasing the statistical power by pooling studies 
using standardized study protocols; improvement of appro-
priate organ and tissue dose assessment, e.g. different parts 
of the heart, main arteries and veins as well as blood, brain, 
eyes, lens,…) further insights will be gained into the risks 
associated with such exposures. In addition, where possible 
and informative, relevant biological endpoints and mark-
ers should be identified and integrated into epidemiological 
investigations (Kreuzer et al. 2015).
Research line 3: impact of radiation exposure 
characteristics
Dose fractionation and dose-rate effects have been observed 
for the induction of non-cancer effects, e.g. low dose-rate 
dependent effects (premature senescence) seen in endothelial 
cells of the cardiovascular system (Yentrapalli et al. 2013; 
Rombouts et al. 2014). The impacts of radiation quality and 
inhomogeneous exposure for non-cancer endpoints are not 
well understood. If non-cancer diseases are included in the 
estimation of health risk at low doses, the radiation weight-
ing factors applied may not be the same as those used for 
cancers and hereditary effects. The underlying mechanisms 
and their response to differing conditions of irradiation will 
need to be understood.
12 Radiation and Environmental Biophysics (2018) 57:5–15
1 3
Key research question 3: “individual 
radiation sensitivity”
Variability in radiation-related health risk and genetic 
susceptibility to radiation effects within a population is 
an important issue for radiation protection. Differences in 
radiation sensitivity between individuals, or groups, may 
relate to gender, age at exposure, attained age, state of 
health, genetic and epigenetic make-up, lifestyle, and co-
exposures. Such differences, if significant, raise the ethi-
cal and policy question as to whether some individuals or 
groups are inadequately protected by the present system 
and regulations, and whether it would be acceptable to 
apply different exposure limits for various subgroups of 
the population or ultimately at the individual level.
At present, there is insufficient information to establish 
how large the differences in sensitivity may be between 
individuals or between groups of individuals and their 
consequent influence on risk estimates at low doses 
and dose-rates. In order to address policy questions it 
is necessary to obtain better knowledge on the extent 
of the variations in sensitivity in the population, both 
in the sizes of the variations and in the proportions of 
the population that are affected. This needs to include 
the impact of dose inhomogeneity, radiation quality, and 
internal versus external exposures. In addition, the nature 
of the interaction of ionising radiation with co-exposures 
to other agents (e.g. tobacco smoke, heavy metals) for 
various cancers is important in considering risk transfer 
between different populations.
Research line 1: basic mechanisms
Basic research is needed to establish which factors and 
processes predispose individuals to greater risk of late 
effects in terms of cancer or non-cancer diseases. This 
includes both molecular epidemiological approaches, the 
discovery of genetic, phenotypic and molecular markers 
of these pathways (Hall et al. 2017; Pernot et al. 2012), 
and the integration of mechanistic studies in the quanti-
tative evaluation of health risks. A major focus should 
be the understanding of how these different factors may 
modify risk keeping in mind that the radiosensitive phe-
notype is likely to be multifactorial. Another important 
question is whether acute or late markers of radiation sen-
sitivity (adverse healthy tissue or organ responses after 
radiotherapy) are related to risk of developing late effects 
following exposure to low and protracted doses of dif-
ferent linear energy transfers (LETs) including internal 
exposures.
Research line 2: health risk evaluation
The quantification of the contribution that individual 
sensitivity makes to radiation risk on both an individual 
and population level is a key question. Realistic estimates 
of how large the differences may be in extreme cases as 
well as the spread of sensitivities in average population 
groups will need large informative epidemiological stud-
ies with reliable information on potential effect modifiers 
and inclusion of molecular biomarkers. Systems biological 
analyses and mechanistically based models of disease are 
further prerequisites.
Research line 3: impact of radiation exposure 
characteristics
The impact of external versus internal emitters, dose inho-
mogeneities and radiation quality on individual radio-
sensitivity related to different doses and dose-rates has 
not been defined for relevant environmental, medical and 
occupational exposures. In case of internal contamina-
tion, individual radio-sensitivity could be dependent on 
localized dose distributions, but currently no mechanis-
tic understanding, relevant experimental models, or valid 
datasets exist for these relationships. Similarly, radiation 
quality is gaining importance because of the more wide-
spread availability of external beam hadrontherapy, where 
scattered neutrons are of concern, and the increasing clini-
cal use of radionuclides (Belli et al. 2010).
Individual sensitivity should be analysed as a function 
of exposure and not only dose, because the same exposure 
can result in very different doses and spatial dose distri-
butions in different individuals. For internal exposure, 
the dose distributions can be very different between indi-
viduals due to anatomical and physiological differences 
(e.g. airway morphology variability, different thickness of 
mucus layer in the bronchi or nose as opposed to mouth 
breathing). This variability should be taken into account 
and modelled for future analysis. Both accurate dosimet-
ric models and physiologically relevant biokinetic mod-
els are required for the interpretation of the health and 
biological effects of internal emitters, especially for the 
characterization of individual sensitivities. There is also 
a need to better characterize how candidate biomarkers, 
identified in response to low LET (linear energy transfer) 
external exposure, may be influenced by internal exposure, 
dose inhomogeneity, radiation quality. In many situations, 
mixed field exposures are relevant but again there are no 
data related to the role of individual radio-sensitivity.
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Education and training (E&T)
The HLEG report of 2009 (http://www.hleg.de/fr.pdf) 
identified a problem with the maintenance in Europe of 
the range of expertise essential to an effective programme 
of research into the risks to humans from low-dose radia-
tion. The report advised that specific programmes aiming 
at knowledge management across generations need to be 
designed in order to achieve sustainable continuity and 
development.
It is important that sponsored courses and workshops 
are provided to attract students into the radiation research 
area. A successful example is the annual series of short 
courses funded by CONCERT (http://www.concert-h2020.
eu/en/Concert_info/Education_Training). A large propor-
tion of the groundwork of research is carried out as stu-
dent projects and thesis work. For this reason, the research 
effort relies on a continuing relationship with universities, 
and on a healthy stream of high-level students. It is, there-
fore, essential that this symbiosis is recognised and taken 
into account in research funding structures.
A further role of E&T within any specialized research 
area is in dissemination of new technologies, skills, and 
knowledge. To obtain maximum impact and benefit from 
research there should be a programme of workshops, 
seminars, summer schools, etc. which is integrated into 
the design and funding structure of all research. The pro-
gramme should be aimed both at sharing knowledge within 
the European low-dose research community and at the 
wider radiation protection field including radioecology, 
emergency response, and the medical use of radiation.
Because the number of centres of expertise in low-dose 
research in Europe is limited, it is important that the cen-
tres collaborate to provide a coordinated E&T programme. 
University courses should be modular, and mutual recogni-
tion agreements should permit students to transfer across 
EU states to construct degree courses. There is a need for 
a forum to facilitate networking and to bring together all 
interested parties regularly to discuss needs and broaden 
the awareness of what is happening in EU member states.
Infrastructures
One of the roles of MELODI is to ensure the availabil-
ity of and to facilitate ready access to the state-of-the-art 
research infrastructures required to support the research 
efforts in low dose research. The priority is to promote 
the use of mature and up-to-date infrastructures and avoid 
unnecessary duplication. Furthermore, an effort should be 
made to harmonize practices amongst multiple facilities. 
Finally, the sustainability of rare but necessary facilities 
(e.g. for internal contamination) needs to be guaranteed. 
This should include recommendations on the provision 
of the financial means to harmonize, sustain and access 
these facilities.
Infrastructures include so-called large infrastructures 
such as exposure facilities including those for animal experi-
mentation, as well as the collection and storage of cohort 
data, databases, biobanks, and analytical platforms.
Within the EU-funded project DoReMi, an extensive 
list of relevant infrastructures was generated for low-dose 
research in particular irradiation facilities for internal and 
external exposure. Concerning relevant epidemiological 
cohorts, priority should be given to cohorts and biobanks 
that permit studies to improve the quantification of the risk 
associated with low dose and low dose-rate radiation expo-
sure, for cancer and/or non-cancer diseases and/or to iden-
tify groups of individuals with specific sensitivity. In the 
short-term, existing epidemiological cohorts can be used 
to support modeling and/or molecular studies for which 
the requirements differ. In the long-term, new prospective 
cohorts can also be envisaged, as well as the development of 
new collections of biological material. Analytical platforms 
that can screen a large set of validated biomarkers (such 
as the European dosimetry network RENEB) are accessible 
for the rapid and reliable assessment of radiation exposure 
(Kulka et al. 2017).
Within the EU-funded project STORE (https://www.
storedb.org/store_v3/), an internet-based platform for shar-
ing data from epidemiological studies, as well as data and 
biological samples from radiation experiments (new and 
past), has been developed, further carried forward and sup-
ported first by DoReMi then by CONCERT. Going forward, 
it will be necessary to promote activities to further update 
and continuously expand the content of the database, and to 
elucidate to what extent data from other radiation protec-
tion platforms (ALLIANCE, NERIS and EURADOS) can be 
incorporated into STORE or whether a comparable database 
would be more appropriate.
Activities to identify valuable materials and archives that 
could be included in the database and the tissue bank, as well 
as to maintain relevant biobanks and rescue material from 
endangered biobanks, need to be supported. The maturation 
of the so-called ‘omics technologies’ and systems biology 
may offer novel opportunities for European radiation pro-
tection research. In order to benefit from the best quality of 
technologies and supporting managerial and technical sup-
port, efforts should be given to facilitating access to major 
national and European infrastructure platforms.
Priority areas related to infrastructures are: (1) improve-
ment of the access to infrastructures, (2) favor open access 
to radiation research data within STORE, (3) re-use of 
archived materials using specific retrospective approaches, 
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(4) enlargement and sustainability of RENEB, including 
inter-comparison exercises, and (5) improvement of the 
knowledge of existing infrastructure via E&T courses.
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